Sarepta Shares Slide Amid Class Action Lawsuits and Analyst Downgrades

Sarepta Therapeutics shares are trading lower after multiple law firms filed class action lawsuits concerning safety issues with its product ELEVIDYS, following reports of patient deaths. Analysts have further compounded the negative sentiment with several downgrades, including Morgan Stanley cutting its price target to $15, while H.C. Wainwright sees zero intrinsic value, indicating a major loss of confidence in the stock's value.